Portugal's medicines authority logged 695 suspected adverse reaction reports for GLP-1 drugs such as Mounjaro and Ozempic between January 2024 and September 2026. Nausea and vomiting lead the list; here is how to report a reaction.
Equalmed says thin margins are pushing generics off the market. The users' association UMG wants more competition instead, noting generics are 52 percent of the Portuguese market against 70 percent in Europe.
Infarmed has approved SNS hospital funding for Kaftrio in patients aged 2 and over without the F508del mutation, and for Vertex's newer once-daily Alyftrek from age 6. Who qualifies, how they get it and what is still unknown.
Infarmed's monthly export suspension list, in force since 6 October, keeps every solid oral form of quetiapine in Portugal, plus 52 scarce presentations from tramadol drops and trazodone to cancer drugs and an asthma inhaler.
Infarmed refused a co-payment for Nilemdo and Nustendi and kept the rare-disease drug Evkeeza out of hospitals over price, but approved Elahere after a deal.
How the state shares the cost of SNS prescriptions, why your choice of brand changes the price, and extra help for low income pensioners and chronic illness.
INFARMED's July report puts patient spending at 571.6 million euros, up 2.1 percent, and the SNS share at 1,179.3 million, up 8.3 percent. The average co-payment per pack actually fell two cents. What rose was volume, and one diabetes class accounts for a third of the increase.
